All Stories

  1. Natural Bioactive Compounds Acting against Oxidative Stress in Chronic, Degenerative, and Infectious Diseases

    Article • Oxidative Medicine and Cellular Longevity, December 2018, Hindawi Publishing Corporation

    Dr Italo Tempera

  2. PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type

    Article • Journal of Virology, July 2018, ASM Journals

    Dr Italo Tempera

  3. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1

    Article • Journal of Virology, July 2016, ASM Journals

    Dr Italo Tempera

  4. Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2

    Article • Molecular and Cellular Biology, September 2015, ASM Journals

    Dr Italo Tempera

  5. Epigenetic regulation of EBV persistence and oncogenesis

    Article • Seminars in Cancer Biology, June 2014, Elsevier

    Dr Italo Tempera

  6. Epigenetic Deregulation of the LMP1/LMP2 Locus of Epstein-Barr Virus by Mutation of a Single CTCF-Cohesin Binding Site

    Article • Journal of Virology, November 2013, ASM Journals

    Dr Italo Tempera

  7. Interpreting the Epstein-Barr Virus (EBV) Epigenome Using High-Throughput Data

    Article • Viruses, April 2013, MDPI AG

    Dr Italo Tempera

  8. EBV Latency Types Adopt Alternative Chromatin Conformations

    Article • PLoS Pathogens, July 2011, PLOS

    Dr Italo Tempera

  9. Biological Effects of MC2050, a Quinazoline-Based PARP-1 Inhibitor, in Human Neuroblastoma and EBV-Positive Burkitt′s Lymphoma Cells

    Article • ChemMedChem, March 2011, Wiley

    Dr Italo Tempera

  10. CTCF Prevents the Epigenetic Drift of EBV Latency Promoter Qp

    Article • PLoS Pathogens, August 2010, PLOS

    Dr Italo Tempera